Percepta -- Bioscience questions answered.Percepta -- Bioscience questions answered.Percepta -- Bioscience questions answered.
bioscience. questions. answered.

In US and Canada Call Toll Free: (877) 597-9236
Everywhere Else Call: (760) 431-6300

Reports

2010 Gene Silencing Dashboard Series 3 -

pic_gene_silencing_series_3Catalog number: 1010GSL
Publication date: October 2010
Company-wide electronic copy: $3,975

Please enquire about single-user* electronic copy pricing
* single-user pricing is intended for small companies, of 40 or less employees, to access The Life Science Dashboard. Please order these copies directly with Percepta Associates.

Overview

Overview

RNA interference continues to emerge as a integral tool used to study the physiological role of gene products in vivo. RNAi-based methods allow researchers to modulate and in many cases virtually eliminate expression of a gene of interest. Systems for delivering RNAs into cells for the purpose of gene silencing include standard transfection technologies, both instrument-mediated and lipid-based, as well as plasmid and viral systems for the inducible expression of siRNAs in vivo.

Percepta’s 2010 Gene Silencing Dashboard™ dives deeply into the characteristics and dynamics of the market for gene silencing products. This 2010 Dashboard provides a snapshot of the current market landscape that can be compared with data from the 2008 and 2007 Gene Silencing Dashboard, providing an ongoing story of how the market is adapting to new products, new competitors and new sales and marketing strategies.

The Gene Silencing Dashboard™ was developed from responses to a 21-question survey completed by 281 scientists predominantly located in North America and Europe. This Dashboard reveals key market indicators for the gene silencing market as a whole as well as for the following methods representing market sub-segments:

  • RNAi screens using siRNA libraries (sets of 50 or more siRNAs)
  • Inducing siRNAs in vivo from a plasmid or other vector in cells
  • Digesting long dsRNA in vivo using dicer or other enzymes
  • Expressing siRNA in vitro for delivery into cells
  • Using PCS mediated siRNA expression cassettes to generate siRNAs
  • Instrument mediated delivery of synthetic siRNAs into cells
  • Lipid mediated delivery of synthetic siRNAs into cells
  • Instrument mediated delivery of plasmids into cells for plasmid-based gene knockdown
  • Lipid mediated delivery of plasmids into cells for plasmid-based gene knockdown
  • Viral delivery of vectors into cells for vector-based gene knockdown
  • Using reporter systems to track gene knockdown

Survey Methodology In July of 2010, Percepta fielded the Gene Silencing Survey to a subset of the company’s panel of life scientists. Individuals were invited by e-mail blast to click through to a webpage at bioanalytix.com where the survey was hosted. Invitations were delivered on July 21, 2010 and results collected through July 29. A total of 281 scientists completed the survey, of which 225 are actively engaged in performing gene silencing experiments and 30 plan to perform gene silencing experiments in the future. Results based on the aggregate of collected responses are revealed in this Gene Silencing Dashboard.

Respondent Demographics

Respondents from the academic, government and commercial market segments are well represented, with 20.8% of respondents employed in an industry setting. 73.0% of respondents are from North America, while 25.1% reside in Europe.
Junior (Lab Tech, Grad Students), mid level (Post-Doc, Lab Manager) and senior (Professor/PI, Group Leader) scientists are well represented in the data set, with the most cited job titles being Scientist/Senior Scientist (24.7% of respondents) and Professor / Principle Investigator (20.8%).

A wide variety of scientific areas of specialization is also evident, led by molecular biology (named by 28.9% of respondents as their primary area of expertise) and cell biology (named by 17.0% of respondents). Oncology research (9.1%) and biochemistry (7.1%) are the only other applications named by more than 7% of respondents.

Small (1-5 scientists), medium (6-20 scientists) and large (>20 scientists) laboratories are well represented: 36.1% of respondents work in labs where 1 to 5 people perform experiments; 51.2% in labs with 6 to 20 experimenters, and the remaining 12.7% in labs with greater than 20 bench scientists.

60.1% of respondents indicated that 1 to 3 people in their laboratories perform gene silencing experiments. An additional 18.5% of survey participants revealed that 4 or 5 individuals perform gene silencing experiments in their labs. Only 7.3% of respondents work in labs where greater than 10 people perform gene silencing experiments.

Table of contents

Table of Contents

  • 6 Figures and Tables
  • 10 Executive Summary
  • 13 Key Findings and Implications
  • 18 Gene Silencing Dashboard
  • 23 Gene Silencing Market Opportunity Matrix
  • 25 Survey Methodology
  • 27 Survey Invitation Text
  • 28 Respondent Demographics
  • 41 Frequency of Performance of Life Science Techniques
  • 46 Frequency of Performance of Various Gene Silencing Methods
  • 73 Reaction Throughput and Market Segment Growth Rates
  • 80 Respondent’s Stated Price Per Reaction
  • 83 Total Market Size, Market Segment Sizes and Total Market Growth Rate
  • 85 Market Shares by Segment (Share of Mention)
  • 119 Customer Satisfaction And Interest In Switching Suppliers
  • 125 Product Features That Influence Purchasing Decisions
  • 129 Primary Downstream Applications
  • 146 Desired Changes to Gene Silencing Products
  • 152 Survey Questionnaire

Figures and Tables

  • 30 Figure 1: Respondent’s Place of Employment
  • 32 Figure 2: Respondent’s Country/Region
  • 34 Figure 3: Respondent’s Job Title
  • 36 Figure 4A: Respondent’s Areas of Expertise/Specialization
  • 37 Figure 4B: Respondent’s Areas of Expertise/Specialization (Molecular Biology Excluded)
  • 40 Figure 5: Number of Employees in Respondent’s Laboratories
  • 43 Figure 6: Percentage of Respondents Performing Various Life Science Techniques at Least a Few Times per Year
  • 49 Figure 7: Percentage of Respondents Performing RNAi/siRNA Experiments
  • 50 Figure 7A: Change in Percentage of Respondents Performing RNAi/siRNA Experiments
  • 51 Figure 8: Percentage of Respondents Performing Various Gene Silencing Techniques at Least a Few Times per Year
  • 53 Figure 9: Percentage of Respondents That Perform RNAi Screens Using siRNA Libraries
  • 54 Figure 9A: Change in Percentage of Respondents that Perform RNAi Screens Using siRNA Libraries
  • 55 Figure 10: Percentage of Respondents That Induce siRNAs in vivo from a Plasmid or Other Vector in Cells
  • 56 Figure 10A: Change in Percentage of Respondents that Induce siRNAs in vivo from a Plasmid or Other Vector in Cells
  • 57 Figure 11: Percentage of Respondents That Digest Long dsRNA in vivo using Dicer or other Enzymes
  • 58 Figure 11A: Change in Percentage of Respondents that Digest Long ds RNA in vivo using Dicer or other Enzymes
  • 59 Figure 12: Percentage of Respondents that Express siRNA in vitro for Delivery into Cells
  • 60 Figure 12A: Change in Percentage of Respondents that Express siRNA in vitro for Delivery into Cells
  • 61 Figure 13: Percentage of Respondents that Use PCR Mediated siRNA Expression Cassettes to Generate siRNAs
  • 62 Figure 13A: Change in Percentage of Respondents that Use PCR Mediated siRNA Expression Cassettes to Generate siRNAs
  • 63 Figure 14: Percentage of Respondents that Deliver Synthetic siRNAs into Cells (Instrument Mediated)
  • 64 Figure 15: Percentage of Respondents that Deliver Synthetic siRNAs into Cells (Lipid Mediated)
  • 65 Figure 16: Percentage of Respondents that Deliver Plasmids into Cells for Plasmid Based Gene Knockdown (Instrument Mediated)
  • 66 Figure 17: Percentage of Respondents that Deliver Plasmids into Cells for Plasmid Based Gene Knockdown (Lipid Mediated)
  • 67 Figure 18: Percentage of Respondents that Deliver Viral Vectors into Cells for Vector Based Gene Knockdown
  • 68 Figure 19: Percentage of Respondents that Use a Reporter Systems to Track Gene Knockdown
  • 69 Figure 19A: Change in Percentage of Respondents that Use a Reporter Systems to Track Gene Knockdown
  • 90 Figure 20: Respondent’s Primary Supplier of Products for Performing RNAi Screens Using siRNA Libraries
  • 91 Figure 20A: Changes in Respondent’s Primary Supplier of Products for Performing RNAi Screens Using siRNA Libraries
  • 93 Figure 21: Respondent’s Primary Supplier of Products to Induce siRNAs in vivo from a Plasmid or Other Vector in Cells
  • 94 Figure 21A: Changes in Respondent’s Primary Supplier of Products to Induce siRNAs in vivo from a Plasmid or Other Vector in Cells
  • 96 Figure 22: Respondent’s Primary Supplier of Products to Digest Long ds RNA in vivo using Dicer or Other Enzymes
  • 97 Figure 22A: Changes in Respondent’s Primary Supplier of Products to Digest Long dsRNA in vivo using Dicer or Other Enzymes
  • 99 Figure 23: Respondent’s Primary Supplier of Products to Express siRNA in vitro for Delivery into Cells
  • 100 Figure 23A: Changes in Respondent’s Primary Supplier of Products to Express siRNA in vitro for Delivery into Cells
  • 102 Figure 24: Respondent’s Primary Supplier of PCR Mediated siRNA Expression Cassettes to Generate siRNAs
  • 103 Figure 24A: Changes in Respondent’s Primary Supplier of PCR Mediated siRNA Expression Cassettes to Generate siRNAs
  • 105 Figure 25: Respondent’s Primary Supplier of Products to Deliver Synthetic siRNAs into Cells (Instrument Mediated)
  • 107 Figure 26: Respondent’s Primary Supplier of Products to Deliver Synthetic siRNAs into Cells (Lipid Mediated)
  • 109 Figure 27: Respondent’s Primary Supplier of Products to Deliver Plasmids into Cells for Plasmid Based Gene Knockdown (Instrument Mediated)
  • 111 Figure 28: Respondent’s Primary Supplier of Products to Deliver Plasmids into Cells for Plasmid Based Gene Knockdown (Lipid Mediated)
  • 113 Figure 29: Respondent’s Primary Supplier of Products for Viral Delivery of Vectors into Cells for Vector Based Gene Knockdown
  • 115 Figure 30: Respondent’s Primary Supplier of Reporter Systems to Track Gene Knockdown
  • 116 Figure 30A: Changes in Respondent’s Primary Supplier of Reporter Systems to Track Gene Knockdown
  • 124 Figure 31: Percentage of Respondents That Have Switched Suppliers in the Last Six Months
  • 127 Figure 32: Most Important Features of Products for Gene Silencing Experiments
  • 132 Figure 33: Respondent’s Primary Downstream Application for RNAi Screens Using siRNA Libraries
  • 133 Figure 34: Respondent’s Primary Downstream Application for Products to Induce siRNAs in vivo from a Plasmid or Other Vector in Cells
  • 134 Figure 35: Respondent’s Primary Downstream Application for Products to Digest Long dsRNA in vivo using Dicer or Other Enzymes
  • 135 Figure 36: Respondent’s Primary Downstream Application for Products to Express siRNA in vitro for Delivery into Cells
  • 136 Figure 37: Respondent’s Primary Downstream Application for PCR Mediated siRNA Expression Cassettes to Generate siRNAs
  • 137 Figure 38: Respondent’s Primary Downstream Application for Products to Deliver Synthetic siRNAs into Cells (Instrument Mediated)
  • 138 Figure 39: Respondent’s Primary Downstream Application for Products to Deliver Synthetic siRNAs into Cells (Lipid Mediated)
  • 139 Figure 40: Respondent’s Primary Downstream Application for Products to Deliver Plasmids into Cells for Gene Knockdown (Instrument Mediated)
  • 140 Figure 41: Respondent’s Primary Downstream Application for Products to Deliver Plasmids into Cells for Gene Knockdown (Lipid Mediated)
  • 141 Figure 42: Respondent’s Primary Downstream Application for Products to Deliver Viral Vectors into Cells for Vector Based Gene Knockdown
  • 142 Figure 43: Respondent’s Primary Downstream Application for Reporter Systems to Track Gene Knockdown
  • 38 Table 1: Respondent’s Areas of Expertise/Specialization Values for Figures 4A and 4B
  • 44 Table 2: Frequency of Performance of Various Life Science Techniques
  • 45 Table 3: Frequency of Co-Performance of Various Life Science Techniques
  • 52 Table 4: Frequency of Performance of Gene Silencing Methods
  • 71 Table 5: Frequency of Co-Performance of Life Science Techniques with Gene Silencing Methods
  • 72 Table 6: Frequency of Co-Performance of Gene Silencing Methods with Life Science Techniques
  • 75 Table 7: Median and Average Monthly Throughput for Gene Silencing Products
  • 76 Table 8: Percentage of Respondents Performing Various Numbers of Gene Silencing Reactions Per Month
  • 77 Table 9: Comparison to 2008 Dashboard of the Percentage of Respondents Performing Various Numbers of Gene Silencing Reactions Per Month
  • 79 Table 10: Projected Growth in the Performance of Various Gene Silencing Techniques
  • 82 Table 11: Median and Average Price Per Prep for Gene Silencing Products
  • 118 Table 12: Market Share Leaders for Gene Silencing Products
  • 121 Table 13: Percentage of Respondents Satisfied with Various Gene Silencing Products and Reasons for Dissatisfaction
  • 122 Table 14: Percentage of Respondents Satisfied with Various Gene Silencing Products: Comparison to 2008 Dashboard
  • 128 Table 15: Most Important Features of Products for Gene Silencing Experiments – Comparison to 2008 Gene Silencing Dashboard
  • 143 Table 16: Respondent’s Primary Application for Various Gene Silencing Methods
  • 145 Table 17: Respondent’s Primary Application for Various Gene Silencing Methods – Comparison to 2008 Gene Silencing Dashboard

Questionnaire

Available upon request

Copyright © 2017 Percepta Associates Inc. All rights reserved. Terms & Conditions.Designed by Audacity